Seattle Genetics Inc. has reach a drug collaboration and license agreement with Pieris Pharmaceuticals Inc. worth up to $1.2 billion.
Seattle Genetics will pay Boston-based Pieris a $30 million up-front fee, royalties on some sales and up to $1.2 billion in milestone payments if the drugs reach their full potential.
The deal combines Seattle Genetics’ anti-drug conjugate technology and Pieris’ Anticalin technology to develop new antibody-Anticalin fusion proteins.
“This partnership leverages…
Seattle Biz Journal
Seattle Genetics inks drug licensing deal worth up to .2 billion